The impact that number of analyzed metastatic breast cancer lesions has on response assessment by 18F-FDG PET/CT using PERCIST

K Pinker, CC Riedl, L Ong, M Jochelson… - Journal of Nuclear …, 2016 - Soc Nuclear Med
The PET Response Criteria in Solid Tumors (PERCIST) are not specific regarding the
number of lesions that should be analyzed per patient. This study evaluated how the number …

[HTML][HTML] A role of FDG-PET/CT for response evaluation in metastatic breast cancer?

MG Hildebrandt, M Naghavi-Behzad… - Seminars in Nuclear …, 2022 - Elsevier
Breast cancer prognosis is steadily improving due to early detection of primary cancer in
screening programs and revolutionizing treatment development. In the metastatic setting …

FDG-PET/CT for response monitoring in metastatic breast cancer: the feasibility and benefits of applying PERCIST

M Vogsen, JL Bülow, L Ljungstrøm, HR Oltmann… - Diagnostics, 2021 - mdpi.com
Background: We aimed to examine the feasibility and potential benefit of applying PET
Response Criteria in Solid Tumors (PERCIST) for response monitoring in metastatic breast …

Response monitoring in metastatic breast Cancer: a prospective study comparing 18F-FDG PET/CT with conventional CT

M Vogsen, F Harbo, NM Jakobsen… - Journal of Nuclear …, 2023 - Soc Nuclear Med
This study aimed to compare contrast-enhanced CT (CE-CT) and 18F-FDG PET/CT for
response monitoring in metastatic breast cancer using the standardized response …

Early prediction of response to chemotherapy in metastatic breast cancer using sequential 18F-FDG PET

JD Schwarz, M Bader, L Jenicke… - Journal of Nuclear …, 2005 - Soc Nuclear Med
Chemotherapy is currently the treatment of choice for patients with high-risk metastatic
breast cancer. Clinical response is determined after several cycles of chemotherapy by …

Interrater agreement and reliability of PERCIST and visual assessment when using 18F-FDG-PET/CT for response monitoring of metastatic breast cancer

JS Sørensen, MH Vilstrup, J Holm, M Vogsen, JL Bülow… - Diagnostics, 2020 - mdpi.com
Response evaluation at regular intervals is indicated for treatment of metastatic breast
cancer (MBC). FDG-PET/CT has the potential to monitor treatment response accurately. Our …

Comparison of FDG-PET/CT and contrast-enhanced CT for monitoring therapy response in patients with metastatic breast cancer

CC Riedl, K Pinker, GA Ulaner, LT Ong… - European journal of …, 2017 - Springer
Purpose The aim of this study was to compare fluorodeoxyglucose positron emission
tomography/computed tomography (FDG PET/CT) and contrast-enhanced computed …

2-[18F]FDG-PET/CT is a better predictor of survival than conventional CT: a prospective study of response monitoring in metastatic breast cancer

M Vogsen, M Naghavi-Behzad, FG Harbo… - Scientific Reports, 2023 - nature.com
This study aimed to compare CE-CT and 2-[18F] FDG-PET/CT for response monitoring
metastatic breast cancer (MBC). The primary objective was to predict progression-free and …

[PDF][PDF] 18 Early assessment of tumor response using F-FDG PET/CT after one cycle of systemic therapy in patients with recurrent and metastatic breast cancer

K Kitajima, T Higuchi, K Yamakado… - Hellenic Journal of …, 2022 - nuclmed.gr
Objective: This study was conducted to evaluate the usefulness of early assessment of tumor
response 18 using fluorine-18-fludeoxyglucose positron emission tomography/computed …

FDG-PET/CT versus contrast-enhanced CT for response evaluation in metastatic breast cancer: a systematic review

F Helland, M Hallin Henriksen, O Gerke, M Vogsen… - Diagnostics, 2019 - mdpi.com
18F-fluorodeoxyglucose positron emission tomography with integrated computed
tomography (FDG-PET/CT) and contrast-enhanced computed tomography (CT) can be used …